Industry News
Biotechnology Industry News
Boehringer Ingelheim has inked a…
Boehringer Ingelheim has inked a deal with Palatin Technologies worth up to €280 million (about $327 million) biobucks with the aim of developing new retinal disease therapies.
Merck KGaA has swooped into a…
Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion.
Reunion Neuroscience’s…
Reunion Neuroscience’s psychedelic has reduced the symptoms of postpregnancy depression in a phase 2 study, setting up the biotech to enter late-stage trials next year.
Pfizer’s sickle cell disease…
Pfizer’s sickle cell disease drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.
Omeros’ efforts to get its…
Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. Now, the biotech’s second shot at approval has been pushed back by three months.
Experienced business developer…
Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a biotech. Hicks most recently was chief business officer at Intellia Therapeutics and before that
Evotec previously planned to lay…
Evotec previously planned to lay off 400 staffers amid a sweeping reorganization. It has actually cut roughly 600 as of June.
Prelude Therapeutics’ lead asset…
Prelude Therapeutics’ lead asset won’t be making it to the second act. The precision oncology outfit is pausing development of SMARCA2 degrader PRT3789, leaving just one clinical program left humming in its pipeline.
Having backed Superluminal…
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.
Schrödinger is abandoning its…
Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial.
A patient has died from kidney…
A patient has died from kidney injury in a trial of CytomX Therapeutics’ lead antibody-drug conjugate, although the biotech has been advised to stick with the study.
Sarepta Therapeutics is selling…
Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals shares to stretch its cash runway, while also inking a share transfer to pay off half of a $100 million payment owed to the latter.
Rosnilimab, a selective depleter…
Rosnilimab, a selective depleter of pathogenic T cells, is a potential game changer for the treatment of moderate-to-severe rheumatoid arthritis (RA).
Vedanta Biosciences’ dreams of…
Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease have been dashed. The Massachusetts-based microbiome outfit’s mixture of 16 bacterial strains failed to reduce disease severity in the colons of patients with
Hatteras Venture Partners has…
Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs alongside medtech and healthtech companies.
Response Pharmaceuticals has…
Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in blood-fat levels and weight gain in previous users of obesity drugs.
Oric’s previously announced plan…
Oric’s previously announced plan to focus resources come with a sting in its tail—the therapeutic resistance-focused biotech is laying off 20% of its employees to finance the strategy.
Generation Bio is shedding 90% of…
Generation Bio is shedding 90% of its workforce after the biotech acknowledged that it’s unlikely to find the cash to take its lipid nanoparticle tech into the clinic.
More bad news has come down for…
More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee to consider the asset’s potential approval in a rare disease, pushing the PDUFA date to
The director of the National…
The director of the National Institutes of Health has attributed the federal government’s discontinuation of mRNA vaccine development to a lack of public trust that has made the platform “no longer viable."